Search CommunityWalk:


Rexahn Pharmaceuticals Inc

15245 Shady Grove Road
Suite 455
Rockville, MD 20850, USA

Category: Biotechnology/Biopharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Rexahn Pharmaceuticals Inc is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments for cancer, central nervous system disorders and other unmet medical needs. The company was founded in 2001 by Chang H. Ahn with a mission to impact the health and wellness of patients with life-threatening and life-debilitating diseases.

Rexahn's discovery platform features small signaling molecule discovery (TIMES), computational predictive modeling (3D-GOLD) and nanoscale drug targeting and delivery. These technologies enable to screen, select and optimize large numbers of compounds while retaining stringent selection criteria. It's proprietary TIMES small molecule signaling technology has enabled it to discover more than a dozen targets involved in cancer proliferation. The company's 3D-GOLD is an integrated computational modeling tool of 3D-finger printing / pharmacophore, 3D-QSAR/proprietary QCID, 3D-ligand constructs, and 3D-dockings, that helps to predict the structural activity relationship of molecules using 3-dimensional models. The company is developing cutting-edge drug delivery systems based on nano-liposome and polymer encapsulation of existing medicines that could increase bio-availability while minimizing adverse reactions.

Rexahn's portfolio presents unique compounds for a wide variety of conditions from cancer to brain disorders and promises to improve the standards of care for multiple diseases. Its development pipeline includes - 1) Cancer: Archexin®, an inhibitor of the Akt-1 protein kinase in cancer cells. It is being developed for the treatment of renal cell carcinoma (RCC) and pancreatic cancer, glioblastoma, and cancers of ovary and stomach. The company's other pipeline products include: RX-0047-N, RX-5902, RX-3117, RX-1792, RX-8243, RX-0201-N, etc; and 2) CNS disorders: Serdaxin® for the treatment of major depressive disorder (MDD) and Parkinson's disease; and Zoraxel™ is a CNS-based sexual dysfunction drug that is being developed to treat erectile dysfunction.

Rexahn has collaborations with United States Department of The Treasury, TheraTarget, Inc., Korea Research Institute of Chemical Technology (KRICT), Teva Pharmaceutical Industries, Ltd., University of Maryland, Amarex Clinical Research, Inc., UPM Pharmaceuticals, Inc., Revaax Pharmaceuticals LLC, etc.